Hormones News and Research

RSS

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Study evaluates association between PBDE flame retardants and thyroid function in pregnant women

Pregnant women with higher blood levels of a common flame retardant had altered thyroid hormone levels, a result that could have implications for fetal health, according to a new study led by researchers at the University of California, Berkeley.

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

Researchers review data comparing IUDs and hormonal contraceptives

Women who have had intrauterine devices fitted as contraceptives are less likely to become pregnant than those who have hormone injections, a new review by Cochrane Researchers has found. The review, which focused on women in developing countries, also found a possible link between contraceptive method and disease progression in HIV.

19 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

Smokeless tobacco affects normal function of CYP-450 family of enzymes: Report

Far from having adverse effects limited to the mouth, smokeless tobacco affects the normal function of a key family of enzymes found in almost every organ in the body, according to the first report on the topic in ACS' monthly journal Chemical Research in Toxicology. The enzymes play important roles in production of hormones, including the sex hormones estrogen and testosterone; production of cholesterol and vitamin D; and help the body breakdown prescription drugs and potentially toxic substances.

17 Jun 2010

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

An article published in the May 2010 issue of Postgraduate Medicine highlights the seriousness of cardiovascular disease (CVD) in patients with type 2 diabetes. Cardiovascular disease is the cause of death in > 65% of patients with diabetes, and when complicated by the presence of obesity, the lifetime risk of developing CVD increases to 90%. The inherent problem is that many of the antihyperglycemic medications used to combat high glycated hemoglobin are associated with weight gain and/or hypoglycemia, which negatively affect CVD.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

Prevention, awareness of enlarged prostate can help save lives

We live in a country of excess where size often matters most. Supersize, grande, max, king size - but is bigger always better? Certainly not when it comes to male health and an enlarged prostate.

16 Jun 2010

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

A hormone that helps to regulate blood sugar levels may also influence a person's sensitivity to sweet-tasting foods, according to a new study from researchers at the University of Maryland School of Medicine. They found that blocking the tongue's ability to respond to the hormone known as glucagon decreases the taste system's sensitivity to sweetness.

16 Jun 2010

ATA members raise concern about reduction in dietary iodine intake

Following publication of an article in the February 18 issue of the New England Journal of Medicine (Vol. 362 No. 7 pp 590-599) by Bibbins-Domingo, et al. that projected the effect of moderate dietary salt reductions on future cardiac disease rates, several members of the American Thyroid Association, concerned about the subsequent potential reduction in availability of iodine, have responded with a letter in the current issue of the NEJM (Vol. 362 No. 23 pp 2224-2226).

15 Jun 2010

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

15 Jun 2010

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Scientists from the University of Leeds have discovered the mechanisms of a protein known to play an active part in the inherited kidney disorder, Dent's disease. The findings provide a new focus for future therapies for the disease, for which there is currently no cure.

15 Jun 2010

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's healthcare products, today announced that it completed a $45 million Series B Preferred Stock financing. The financing round was co-led by Investor Growth Capital and Care Capital, with strong participation from ProQuest Investments. Kaiser Permanente Ventures and Novitas Capital also joined the financing round. Investor Growth Capital, Care Capital, and Kaiser Permanente Ventures are new investors to Agile.

14 Jun 2010

Type 2 diabetes doubles risk of cancer in women

Type 2 adult-onset diabetes causes insulin-like hormones to circulate through the body. A new study finds this has a surprisingly positive effect on reducing the rate of prostate cancer in men, but is bad news for women: Type 2 diabetes may double the risk of female genital and other cancers.

11 Jun 2010

Differences in immune systems of men and women can impact diseases: Research

In the book Sex Hormones and Immunity to Infection, Sabra Klein, PhD, assistant professor at the Johns Hopkins Bloomberg School of Public Health's W. Harry Feinstone Department of Molecular Microbiology and Immunology, explores the differences in the immune systems of men and women and how these differences can impact disease.

10 Jun 2010

Biofeedback training on MPA decreases performance anxiety, improves performance in musicians

Traditionally, the most successful methods used to combat stage fright have been prescribed medications (beta blockers) and aerobic exercise. In the most recent issue of Biofeedback, researchers studied another technique: the effect of biofeedback training on Musical Performance Anxiety (MPA). MPA is a severe form of stage fright marked by high anxiety levels and impaired performance.

9 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Hormones News and Research

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Study evaluates association between PBDE flame retardants and thyroid function in pregnant women

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Researchers review data comparing IUDs and hormonal contraceptives

FDA approves Jevtana to treat men with prostate cancer

Smokeless tobacco affects normal function of CYP-450 family of enzymes: Report

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

Stress-related psychiatric disorders more common among women: Study

Prevention, awareness of enlarged prostate can help save lives

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

ATA members raise concern about reduction in dietary iodine intake

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Type 2 diabetes doubles risk of cancer in women

Differences in immune systems of men and women can impact diseases: Research

Biofeedback training on MPA decreases performance anxiety, improves performance in musicians

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News